The global longevity and healthy ageing sector sits at an unprecedented inflection point between fundamental biological innovation and consumer health commercialisation. Driven by demographic shifts that will see the population aged 80 and older reach 265 million by the mid-2030s, alongside a widening healthspan-lifespan gap currently estimated at ten years in developed markets, the sector has attracted intense institutional, corporate and private equity interest.